Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT04234048. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
Study identification
- NCT ID
- NCT04234048
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 46 participants
Conditions and interventions
Conditions
- T-cell Lymphoma
- Cutaneous/Peripheral T-Cell Lymphoma
- Peripheral T-cell Lymphoma
- Peripheral T-Cell Lymphoma, Not Classified
- Primary Cutaneous T-cell Lymphoma
- Cutaneous T-Cell Lymphoma, Unspecified
- Cutaneous T-cell Lymphoma
- Follicular T-Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Sézary's Disease
- Mycosis Fungoides
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2023 (Actual)
- Primary completion
- Jun 1, 2028 (Estimated)
- Completion
- Nov 1, 2028 (Estimated)
- Last update posted
- Oct 5, 2026
2023 – 2028
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | Recruiting |
| City of Hope Medical Foundation | Duarte | California | 91010 | Recruiting |
| University of Southern California | Los Angeles | California | 90007 | Recruiting |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | Recruiting |
| Northwestern University, Robert H. Lurie Comprehensive Cancer Center | Chicago | Illinois | 60611 | Recruiting |
| University of Michigan | Ann Arbor | Michigan | 48109 | Recruiting |
| Barbara Ann Karmanos Cancer Institute Wayne State University | Detroit | Michigan | 48201 | Recruiting |
| Columbia University | New York | New York | 10032 | Recruiting |
| University of Pittsburgh Medical Center (UPMC) | Pittsburgh | Pennsylvania | 15219 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04234048, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 5, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04234048 live on ClinicalTrials.gov.